Announcement of Resolutions of the Fourth Meeting of the Second Supervisory Board
Securities code: 688443 Securities abbreviation: Zhixiang Jintai Announcement number: 2025-045
Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
The Company's Supervisory Committee and all supervisors guarantee that there are no false records, misleading statements or major omissions in this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
1. Convening of Supervisory Board Meetings
The notice and relevant materials for the fourth meeting of the second board of supervisors of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") were issued on October 27, 2025. The meeting was held at 10 a.m. on October 29, 2025 in the company's conference room via on-site communication and communication. 3 supervisors should be present at the meeting, and 3 supervisors were actually present. The meeting was chaired by Yang Jiaqian, chairman of the Board of Supervisors. The convening and holding of the meeting complied with the provisions of relevant laws, regulations and the "Articles of Association of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.".
2. Review status of the Supervisory Board meeting
After deliberation and voting by the supervisors present at the meeting, the meeting resolutions were as follows:
(1) Consideration and approval of the "Proposal on Cancellation of the Board of Supervisors, Amendment of the Articles of Association, and Processing of Industrial and Commercial Change Registration"
In accordance with relevant regulations such as the "Company Law of the People's Republic of China (Revised in 2023)" (hereinafter referred to as the "Company Law"), the China Securities Regulatory Commission's "Transitional Arrangements Related to the Implementation of the New Company Law's Supporting System Rules" and the "Guidelines on the Articles of Association of Listed Companies (Revised in 2025)", combined with the actual development of the company, the company will no longer have a board of supervisors, and the audit committee under the company's board of directors will exercise the powers of the board of supervisors stipulated in the "Company Law" and other laws and regulations. The "Rules of Procedure of the Supervisory Board of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd." shall be abolished accordingly. The provisions of the company's various rules and regulations involving the board of supervisors and supervisors no longer apply. Relevant provisions in the "Articles of Association of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd." shall be revised. At the same time, the board of directors shall propose to the shareholders' meeting to authorize the company's management to handle procedures such as industrial and commercial change registration and articles of association filing. Changes and filing registration shall be subject to the content approved by the market supervision and management authority. Before the company's general meeting of shareholders considers and approves the cancellation of the board of supervisors, the company's second board of supervisors will still perform its duties in strict accordance with laws, regulations and normative documents. All supervisors voted unanimously.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions.
For details, please refer to the "Announcement on Cancellation of the Board of Supervisors, Revision of the Articles of Association and Partial Governance Systems of the Company" (Announcement No. 2025-047) disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) and designated information disclosure media.
This proposal still needs to be submitted to the shareholders' meeting for review.
(2) Consideration and approval of the “Proposal on the Company’s 2025 Third Quarterly Report”
The company has prepared the "2025 Third Quarter Report" in accordance with the law. The relevant content is true, accurate and complete, reflecting the company's actual situation during the reporting period. There are no false records, misleading statements or major omissions. All supervisors voted unanimously.
Voting results: 3 votes in favor, 0 votes against, and 0 abstentions.
For details, please refer to the "2025 Third Quarter Report" disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) and designated information disclosure media.
Announcement is hereby made.
Board of Supervisors of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
October 31, 2025